

'Value Creation; Eisai Way'

Ken Fujiyoshi
Director, Investor Relations
Eisai Co., Ltd.

September 14, 2005

Safe Harbor Statement

- Materials and information provided during this presentation may contain so-called “forward-looking statements”. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from these statements.
- Risks and uncertainties include general industry and market conditions, and general domestic and international economic conditions such as interest rate and currency exchange fluctuations. Risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, technological advances and patents attained by competitors, challenges inherent in new product development, including completion of clinical trials; claims and concerns about product safety and efficacy; obtaining regulatory approvals; domestic and foreign healthcare reforms; trends toward managed care and healthcare cost containment, and governmental laws and regulations affecting domestic and foreign operations.
- Also, for products that are approved, there are manufacturing and marketing risks and uncertainties, which include, but are not limited to, inability to build production capacity to meet demand, unavailability of raw materials, and failure to gain market acceptance.
- The Company disclaims any intention or obligation to update or revise any forward-

Value Creation

Patient Value

Shareholder Value

Employee Value

Patient Value

Fulfillment of unmet medical needs

Stable supply of quality products

**Provision of pharmaceutical product
safety and efficacy information**

Pipeline Policy

1. Area Focus


Neurology

GI

Oncology and Critical Care


2. First-in-class drug

3. Active business development




Filling Pipeline in Neurology Area

**with Focus on
Neurodegenerative
Disease**



Tumor Regression



**Tumor
Suppression**





Shareholder Value

Growth

Return to shareholders

Investor Relations

Future Growth Drivers

1. Pipeline - **All first-in-class type of drugs**

E2007 : AMPA Receptor Antagonist	POC Success
E7389 : Microtubule Growth Suppressor	POC Success
E5564 : Endotoxin Antagonist	POC Success
E5555 : PAR-1 Receptor Antagonist	Phase I
E2012 : γ Secretase Modulator	Pre-Clinical

2. Global Opportunities (FY2000 - FY2004)

49.7% of Net Sales, 59.0% of Operating Income Attributed to Overseas

Net Sales	CAGR 21.7%
Overseas Operating Income*	CAGR 37.9%
Consolidated Net Sales	CAGR 10.2%
Consolidated Operating Income	CAGR 10.2%

3. Strong Current Products (FY2000 - FY2004)

Aricept	CAGR 23.0%
Aciphex/Pariet	CAGR 24.7%

‘Active New Indications

Formulations Research’

* Operating income before Royalty deduction

Proof of Concept Success

-Three First-in-class compounds-

- **E2007: Oral AMPA receptor antagonist**
 - Ph IIb study in Parkinson's disease demonstrated clinically meaningful efficacy (OFF time reduction) and good safety
 - Target NDA/MAA in 2Q FY2007
 - Ph IIb studies ongoing in migraine prophylaxis and epilepsy, in preparation for multiple sclerosis
- **E7389: Microtubule growth suppressor**
 - Considerable objective tumor responses were observed in Breast and Non-small cell lung cancers. – those patients had been treated with chemotherapies including taxanes
 - No severe neurotoxicities have been observed
 - Aiming Subpart-H submission in FY2006
- **E5564 (eritoran): Endotoxin antagonist**
 - A placebo-controlled Ph IIb study in patients with severe sepsis showed more than 5% decrease in mortality in high-dose E5564-treated group, with clear dose response
 - Good tolerability was demonstrated
 - Global Ph III study to be initiated in FY2005
 - Target NDA/MAA in FY2008


Or

US
Sales

Financial Performance & Forecast

	FY2005 1Q					
	Results	%	YOY			YOY
	135.8	100.0	111			108
Adjusted Earnings	103.0	17.9	105			
Gross Margin	111.7	82.3	113	472.0	82.1	109
R&D Expenses	19.9	14.7	110	89.0	15.5	114
SG&A Expenses	69.3	51.1	112	292.0	50.8	108
Operating Income	22.5	16.5	120	91.0	15.8	105
Ordinary Income	23.4	17.2	120	180.0	31.3	109
Net Income	14.9	11.0	120	58.0	10.1	104
EPS (Yen)	52.2		121	203.0		105

Raising the Dividend on Equity [DOE] ratio



'Corporate Value Enhancement through Communication with Shareholders'

U.S. Operation Update

Hajime Shimizu
Chairman and CEO

Eisai, Inc.

September 14, 2005

Performance of Eisai Inc.


(millions of dollars, %)

	FY2003		FY2004			
	Results	%	Results	%	YOY	Increase
Total Revenue	1,734	100.0	2,001	100.0	115	267
<i>Aricept</i> [®]	777	44.8	907	45.3	117	130
<i>Aciphex</i> [®]	933	53.8	968	48.4	104	35
<i>Zonegran</i> [®]	-	-	104	5.2	-	104
Operating Income	88	5.1	96	4.8	109	8
Net Income	53	3.1	62	3.1	115	8

Operating Income (Pre-royalty deduction)	301	17.4	402	20.1	133	101
---	-----	------	-----	------	-----	-----

Eisai Inc.'s Continuing Growth

- Rasagiline Deal Signing
- Rufinamide Deal Signing
- Zonegran Acquisition



Sales of Major Products

(billions of yen, %)

Sales of Major Products

24.8

25.3

102

0.4

Aricept and Aciphex/Pariet Lifecycle Management

Products	Indications Formulations	Status
<i>Aricept</i> Alzheimer's Treatment	Vascular dementia	Plan to submit additional data to FDA and resubmit in EU (FY2005)
	Severe Alzheimer's disease	Filed in August 2005 (US) Plan to file in 3Q FY2005 (EU, JP)
	Mild cognitive impairment (MCI)	Phase III (US)
	Sustained release formulation	Phase I (US)
<i>Aciphex/ Pariet</i> Proton Pump Inhibitor	H. Pylori eradication	Filed in March 2005 (Japan)
	Non-erosive GERD	Phase III (Japan)
	Extended release formulation	Phase I (US)

Entry Strategy

- Eisai chose a strategy of a partnering to enter the US market and commercialize its key products.
- Co-promote agreements with Pfizer and Janssen enabled the company to target key customer segments while avoiding excessive up-front expenditure in infrastructure and allowing growth of the business in a sensible fashion.
- Some of our peer Japanese companies adopted different strategies however.

Learning from Experience

- Co-promote structures were pursued that allowed Eisai to

Continuing US Investment

1987 - 1996: Pre-launch

- Build research, clinical development, and production infrastructure
- Establish sales/marketing capabilities

1987-1989:	<i>Eisai Res. Inst. - Basic Research (MA)</i>	\$18M
1988:	<i>Eisai America Inc - Clinical Development (NJ)</i>	\$1M
1992 – 1993:	<i>Eisai Corp. NA - US Holding Co. (NJ)</i>	\$1M
1994 – 1996:	<i>Eisai Merrimack Valley - Process Research (MA)</i>	\$20M
1995 – 1996:	<i>Eisai Inc– Sales & marketing (NJ)</i>	\$20M
1995 – 1996:	<i>Eisai Inc (RTP) - Production (NC)</i>	\$21M

Continuing US Investment

1997-2001: Launch Stage

- Major investment in promotional spend
- Co-promotions leverage partner expertise and resources

1997:	<i>Eisai Inc– Sales & Marketing (NJ)</i>	\$26M
1997:	<i>Eisai Inc (RTP) - Production (NC)</i>	\$16M
1997 – 1998:	<i>Eisai Res. Inst.- Basic Research (MA)</i>	\$27M



Eisai Research Institute has begun construction of a 150,000 sq. ft. research building in Andover, Mass. This building expansion will include a new laboratory facility consisting of chemistry, biology, drug safety disposition and pharmacology research facility, with conference areas, offices and library. Special support spaces include highly automated laboratories and a large conference room. Project is scheduled for completion in Summer 2006.

Steady Expansion of Sales Capabilities

- Eisai has continually expanded its sales capabilities in order to effectively engage key customer segments, compete in managed markets, and fulfill our goal of becoming independently capable.

FY1996	FY1998	FY2002	FY2004	FY2005...
		<ul style="list-style-type: none"> Medical Reps (250) 	<ul style="list-style-type: none"> Primary Care Team (400) Neurology Team (100) CNS Team (100) Hospital Team (18: Reps + DMs) Enhanced Managed Care Capabilities (16) <i>Total (634)</i> 	<ul style="list-style-type: none"> Hospital LTC Oncology